Abstract
Objective To investigate the safety and effect of azithromycin combined with methylprednisolone for children with refractory mycoplasma pneumonia, and explore the clinical value of the combined application. Methods 120 children with refractory mycoplasma pneumonia admitted to our hospital from January 2015 to January 2017 were selected, and were randomly divided into the control group and the research group, 60 cases in each group. Conventional treatment was implemented in both two groups, including abatement of fever, relieving cough. The control group was treated with intravenous drip of azithromycin 10 mg/(kg•d), after every 4 days, stopping 3 days, 7 days as a treatment course, lasting for 2 courses. On the basis, the research group was treated with intravenous drip of methylprednisolone 2 mg/(kg•d), and then oral prednison tablets 1 mg/(kg•d) after clinical symptoms improving and temperature returning to normal. Results The time of temperature recovery, cough disappearance, pulmonary rales disappearance, and hospitalization of the research group were significantly shorter than those of the control group (P 0.05). Conclusion Azithromycin combined with methylprednisolone in the treatment of children with refractory mycoplasma pneumonia can improve the curative effect, improve the immune function, and has high safety, which is worthy of clinical promotion. Key words: Azithromycin; Glucocorticoid; Children; Refractory mycoplasma pneumonia
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
